Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
October 30 2023 - 8:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company")
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company
focused on in-licensing, developing, and commercializing novel
medicines for patients living with rare diseases, today announced
that Catalyst will participate in the upcoming 11th Annual Epilepsy
Awareness Day & Education Expo, taking place at the Disneyland
Hotel in Anaheim, CA, October 30-31, 2023, to raise awareness and
education with the epilepsy community. This event is jointly
organized by Sofie's Journey and Epilepsy Alliance of America and
is the largest gathering of patients, families, and physicians in
the U.S.
Dedicated to helping patients living with
epilepsy and addressing the challenges in diagnosis and treatment,
Catalyst proudly supports this important event. With over 3.4
million people in the U.S. affected by epilepsy, our partnership
underscores a shared commitment to raising awareness and making a
positive impact on those affected and their families. Together, we
aim to advance education, provide support, and advocate for
individuals impacted by epilepsy.
"Over our eleven-year journey engaging with the
epilepsy patient community, we are thrilled to welcome Catalyst as
a partner with epilepsy advocacy groups in support of the important
need of raising further awareness of this disease state," stated
Brad Levy, Co-founder of Epilepsy Awareness Day Organization, and
Sofie's Dad. "In our pursuit of continuing to deliver valuable
educational programs to patients and caregivers affected by
epilepsy, Catalyst’s partnership further aids us in achieving these
goals. We eagerly look forward to collaborating with the Catalyst
team to broaden our reach and raise further awareness in our
patient community."
For additional information and to register for the event, visit
https://epilepsyawarenessday.org/.
About Catalyst Pharmaceuticals
With exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's flagship U.S. commercial
product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for
adults and for children ages six to seventeen. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for AGAMREE (vamorolone) oral suspension 40 mg/mL, a
novel corticosteroid treatment for Duchenne Muscular Dystrophy.
AGAMREE previously received FDA Orphan Drug and Fast Track
designations and was approved for commercialization in the U.S. FDA
on October 26, 2023.
For more information about Catalyst
Pharmaceuticals, Inc., visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, visit www.firdapse.com. For Full
Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2022 and its other
filings with the U.S. Securities and Exchange
Commission ("SEC"), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Contacts:
Media Contact:
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Investor Relations:
Mary Coleman, Catalyst Pharmaceuticals
mcoleman@catalystpharma.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Oct 2023 to Oct 2024